Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010.

Kaniski F, Enewold L, Thomas A, Malik S, Stevens JL, Harlan LC.

Lung Cancer. 2017 Jan;103:66-74. doi: 10.1016/j.lungcan.2016.11.020.

PMID:
28024699
2.

Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.

Schabath MB, Cress D, Munoz-Antonia T.

Cancer Control. 2016 Oct;23(4):338-346.

3.

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.

Villaruz LC, Socinski MA.

Eur J Cancer. 2016 Mar;56:162-71. doi: 10.1016/j.ejca.2015.12.022. Review.

4.

Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States.

Speicher PJ, Gu L, Gulack BC, Wang X, D'Amico TA, Hartwig MG, Berry MF.

Clin Lung Cancer. 2016 Jan;17(1):47-55. doi: 10.1016/j.cllc.2015.07.005.

5.

Lung cancer care: the impact of facilities and area measures.

Lathan CS.

Transl Lung Cancer Res. 2015 Aug;4(4):385-91. doi: 10.3978/j.issn.2218-6751.2015.07.23. Review.

6.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH; American Society of Clinical Oncology Clinical Practice..

J Clin Oncol. 2015 Oct 20;33(30):3488-515. doi: 10.1200/JCO.2015.62.1342. Erratum in: J Clin Oncol. 2016 Apr 10;34(11):1287.

7.

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.

Langer CJ, Hirsh V, Okamoto I, Lin FJ, Wan Y, Whiting S, Ong TJ, Renschler MF, Botteman MF.

Br J Cancer. 2015 Jun 30;113(1):20-9. doi: 10.1038/bjc.2015.181.

8.

Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations.

Gerber DE, Lakoduk AM, Priddy LL, Yan J, Xie XJ.

Oncologist. 2015 Jun;20(6):674-82. doi: 10.1634/theoncologist.2015-0083.

9.

Non-Small-Cell Lung Cancer Clinicopathologic Features and Survival Outcomes in Asian Pacific Islanders Residing in the United States: A SEER Analysis.

Hamid MS, Shameem R, Gafoor K, George J, Mina B, Sullivan K.

J Cancer Epidemiol. 2015;2015:269304. doi: 10.1155/2015/269304.

10.

Race, insurance type, and stage of presentation among lung cancer patients.

Efird JT, Landrine H, Shiue KY, O'Neal WT, Podder T, Rosenman JG, Biswas T.

Springerplus. 2014 Dec 3;3:710. doi: 10.1186/2193-1801-3-710.

11.

Lung and colorectal cancer treatment and outcomes in the Veterans Affairs health care system.

Zullig LL, Williams CD, Fortune-Britt AG.

Cancer Manag Res. 2015 Jan 14;7:19-35. doi: 10.2147/CMAR.S75463. Review.

12.

Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).

Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S; Alliance for Clinical Trials in Oncology..

J Natl Cancer Inst. 2014 Nov 27;107(1):336. doi: 10.1093/jnci/dju336.

13.

Racial diversity of actionable mutations in non-small cell lung cancer.

Bollig-Fischer A, Chen W, Gadgeel SM, Wenzlaff AS, Cote ML, Schwartz AG, Bepler G.

J Thorac Oncol. 2015 Feb;10(2):250-5. doi: 10.1097/JTO.0000000000000420.

14.

Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis.

Koshy M, Malik R, Spiotto M, Mahmood U, Weichselbaum R, Sher D.

J Thorac Oncol. 2015 Feb;10(2):264-71. doi: 10.1097/JTO.0000000000000418.

15.

Opportunities to address lung cancer disparities among African Americans.

Coughlin SS, Matthews-Juarez P, Juarez PD, Melton CE, King M.

Cancer Med. 2014 Dec;3(6):1467-76. doi: 10.1002/cam4.348. Review.

16.

Outcomes after treatment of 17,378 patients with locally advanced (T3N0-2) non-small-cell lung cancer.

Speicher PJ, Englum BR, Ganapathi AM, Onaitis MW, D'Amico TA, Berry MF.

Eur J Cardiothorac Surg. 2015 Apr;47(4):636-41. doi: 10.1093/ejcts/ezu270.

17.

Provider-based research networks demonstrate greater hospice use for minority patients with lung cancer.

Penn DC, Stitzenberg KB, Cobran EK, Godley PA.

J Oncol Pract. 2014 Jul;10(4):e182-90. doi: 10.1200/JOP.2013.001268.

18.

Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancer.

Sullivan DR, Ganzini L, Lopez-Chavez A, Slatore CG.

Psychooncology. 2014 Nov;23(11):1318-22. doi: 10.1002/pon.3528. No abstract available.

19.

Race by sex differences in depression symptoms and psychosocial service use among non-Hispanic black and white patients with lung cancer.

Traeger L, Cannon S, Keating NL, Pirl WF, Lathan C, Martin MY, He Y, Park ER.

J Clin Oncol. 2014 Jan 10;32(2):107-13. doi: 10.1200/JCO.2012.46.6466.

20.

Do HIV-infected non-small cell lung cancer patients receive guidance-concordant care?

Lee JY, Moore PC, Steliga MA.

Med Care. 2013 Dec;51(12):1063-8. doi: 10.1097/MLR.0000000000000003.

Supplemental Content

Support Center